Edition:
United Kingdom

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

11.27USD
23 Apr 2018
Change (% chg)

$-0.02 (-0.18%)
Prev Close
$11.29
Open
$11.30
Day's High
$11.55
Day's Low
$11.06
Volume
100,733
Avg. Vol
219,091
52-wk High
$14.45
52-wk Low
$2.54

Latest Key Developments (Source: Significant Developments)

Fate Therapeutics Q4 Loss Per Share $0.29​
Monday, 5 Mar 2018 

March 5 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q4 REVENUE $1.0 MILLION.QTRLY ‍LOSS PER SHARE $0.29​.Q4 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S.  Full Article

Fate Therapeutics Announces Pricing Of Public Offering Of Common Stock
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 9.53 MILLION COMMON SHARES PRICED AT $4.20PER SHARE.  Full Article

Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy
Wednesday, 16 Aug 2017 

Aug 16 (Reuters) - Fate Therapeutics Inc :Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy.Fate Therapeutics Inc - patent covering use of prostaglandins as viral transduction enhancers for genetic modification of cd34hematopoietic cells​.Fate Therapeutics Inc - ‍patent expires in 2029, is owned by Indiana University research and technology corporand is licensed exclusively to co.  Full Article

Fate Therapeutics files for mixed shelf of upto $100 mln
Tuesday, 15 Aug 2017 

Aug 15 (Reuters) - Fate Therapeutics Inc ::Fate Therapeutics Inc files for mixed shelf of upto $100 million - SEC filing.Fate Therapeutics Inc says in addition, selling stockholder may from time to time, offer and sell up to 1 million shares of common stock - SEC filing‍​.Fate Therapeutics Inc says it will not receive any of the proceeds from the sales of common stock from the selling stockholder‍​.  Full Article

Fate Therapeutics Q2 ‍net loss per common share $0.23​
Monday, 14 Aug 2017 

Aug 14 (Reuters) - Fate Therapeutics Inc :Fate Therapeutics reports second quarter 2017 financial results.Q2 revenue $1.0 million versus I/B/E/S view $937,000.Fate Therapeutics Inc - qtrly ‍net loss per common share, basic and diluted $0.23​.Q2 earnings per share view $-0.24, revenue view $936600.00 -- Thomson Reuters I/B/E/S.  Full Article

Fate Therapeutics says FDA cleared third IND application for Fate-NK100​
Tuesday, 8 Aug 2017 

Aug 8 (Reuters) - Fate Therapeutics Inc ::Says ‍U.S. Food and Drug Administration cleared third Investigational New Drug (IND) application for Fate-NK100​.  Full Article

Fate Therapeutics to amend and restate loan and security agreement
Friday, 14 Jul 2017 

July 14 (Reuters) - Fate Therapeutics Inc :Fate Therapeutics Inc - on July 14, 2017 co entered into first amendment to amended and restated loan and security agreement - SEC filing.Fate Therapeutics - SVB loan amendment amends certain amended and restated loan and security agreement between company and bank, dated as of July 30, 2014.Fate Therapeutics Inc - term loan matures on January 1, 2022.Fate Therapeutics - pursuant to SVB loan amendment, bank extended an additional term loan to company on July 14, 2017 in principal amount of $15 million.Fate Therapeutics Inc - from August 1, 2017 through January 1, 2019 company is required to make monthly payments of interest only.  Full Article

Fate Therapeutics reports Q1 loss per share of $0.24
Monday, 15 May 2017 

May 15 (Reuters) - Fate Therapeutics Inc :Reports first quarter 2017 financial results.Q1 revenue $1.0 million versus I/B/E/S view $947,000.Qtrly net loss per common share, basic and diluted $0.24.Research and development expenses were $8.0 million for Q1 of 2017 compared to $6.6 million for comparable period in 2016.  Full Article

Fate Therapeutics announces FDA clearance of investigational new drug application for FATE-NK100
Wednesday, 10 May 2017 

May 10 (Reuters) - Fate Therapeutics Inc :Fate Therapeutics announces FDA clearance of investigational new drug application for FATE-NK100 in advanced solid tumors.  Full Article

Fate Therapeutics qtrly net loss per common share $ 0.21
Thursday, 16 Mar 2017 

Fate Therapeutics Inc : Fate Therapeutics reports fourth quarter 2016 financial results . Q4 revenue $1.0 million versus I/B/E/S view $958,000 . Qtrly net loss per common share $ 0.21 . Fate Therapeutics Inc - cash, cash equivalents and short-term investments as of dec 31, 2016 were $92.1 million compared to $64.8 million as of dec 31, 2015 .Q4 earnings per share view $-0.29, revenue view $957500.00 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Fate Therapeutics Announces Additional Clinical Data From Phase 1 Stage Of Protect Clinical Trial Of Protmune

* FATE THERAPEUTICS ANNOUNCES ADDITIONAL CLINICAL DATA FROM PHASE 1 STAGE OF PROTECT CLINICAL TRIAL OF PROTMUNE™